Reading Time: 7 minutesHi, I’m Heather, a PhD student from King’s College London, and a Communications Ambassador for the 34th International Symposium on ALS/MND which was held in Basel last December. Over 1,300 attendees from around the world gathered to connect with researchers and people affected by MND and engage with the latest research presented in the platform presentation and poster sessions. In this blog post, I will be sharing several of my personal highlights of the symposium, which cover how differences in our genetic code can be explored to understand their effects on MND risk and progression.

Read More

Reading Time: 5 minutes"New drug reduces risk of death by 50%"

You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.

Read More

Reading Time: 4 minutesIn our brains, specific areas control the movement of different body parts (see image below). As we know, MND is a complex disease with a lot of variation between individuals who are affected. For example, symptoms may start in different body parts for different individuals. Understanding why this happens may help us predict the disease onset site or progression across the body in the future.

Read More

Reading Time: 5 minutesHi, my name is Avril Mc Tague. I am undertaking a Ph.D. at Trinity College, Dublin, Ireland as part of the Multidisciplinary Innovation and Research Advancing Neurological care in a Digital Age (MIRANDA) doctoral award programme. This is funded by the Health Research Board in Ireland. I was one of five symposium communication ambassadors at last year’s international symposium.

Read More